Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains

Journal of Translational Medicine

Volumn 13, Issue 1, 2015, Pages

  Sironi, Francesca ^a   Malnati, Mauro ^a   Mongelli, Nicola ^b   Cozzi, Paolo ^b   Guzzo, Christina ^c   Ghezzi, Silvia ^a   Martínez Romero, Carles ^b,d   García Sastre, Adolfo ^b,d   Lusso, Paolo ^c   Jabes, Daniela ^e   Biswas, Priscilla ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b Unit of Viral Pathogens and Biosafety Division of Immunology Transplantation and Infectious Diseases San Raffaele Hospital ^*  (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e NeED Pharmaceuticals   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; DISTAMYCIN A; GAG PROTEIN; GLYCOPROTEIN GP 120; MARAVIROC; MONOCLONAL ANTIBODY; ND 4040; ND 4041; ND 4042; ND 4043; PLERIXAFOR; SURADISTA DERIVATIVE; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; CYCLOHEXANE DERIVATIVE; HETEROCYCLIC COMPOUND; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; TRIAZOLE DERIVATIVE;

ANIMAL CELL; ANTIBODY COMBINING SITE; ANTIGEN ANTIBODY COMPLEX; ANTIVIRAL ACTIVITY; ARTICLE; CELL POPULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG HALF LIFE; DRUG SCREENING; GENE ACTIVATION; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 6; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFLUENZA VIRUS; MALE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN DETERMINATION; REPORTER GENE; VACCINIA VIRUS; VIRUS CELL INTERACTION; VIRUS CHARACTERIZATION; VIRUS CULTURE; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS STRAIN; 3T3 CELL LINE; ANIMAL; CELL DEATH; CELL LINE; DRUG EFFECTS; FLOW CYTOMETRY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEMBRANE FUSION; METABOLISM; PATHOLOGY; PHYSIOLOGY; VIROLOGY;

3T3 CELLS; ANIMALS; ANTIVIRAL AGENTS; CELL DEATH; CELL LINE; CYCLOHEXANES; FLOW CYTOMETRY; HETEROCYCLIC COMPOUNDS; HIV ENVELOPE PROTEIN GP120; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MEMBRANE FUSION; MICE; RECEPTORS, CCR5; RECEPTORS, CXCR4; TRIAZOLES; VIRUS INTERNALIZATION; VIRUS REPLICATION;

EID: 84927934686     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-015-0461-9     Document Type: Article

References (54)

1. De Clercq E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Ag. 2009;33:307-20.
2. Town BW, Wills ED, Wormall A. Action of suramin on enzymes. Nature. 1949;163:735.
3. Wills ED, Wormall A. Studies on suramin; the action of the drug on some enzymes. Biochem J. 1950;47:158-70.
4. Arcamone F, Penco S, Orezzi P, Nicolella V, Pirelli A. Structure and synthesis of distamycin A. Nature. 1964;203:1064-5.
5. Mitsuya H, Popovic M, Yarchoan R, Matsushita S, Gallo RC, Broder S. Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III. Science. 1984;226:172-4.
6. Broder S, Collins JM, Markham PD, Redfield RR, Hoth DF, Groopman JE, et al. Effects of suramin on HTLVIII/LAV infection presenting as Kaposi's sarcoma or AIDS-related complex: clinical pharmacology and suppression of virus replication in vivo. Lancet. 1985;326:627-30.
7. Cheson BD, Levine AM, Mildvan D, Kaplan LD, Wolfe P, Rios A, et al. Suramin therapy in AIDS and related disorders. Report of the US suramin working group. JAMA. 1987;258:1347-51.
8. Siccardi AG, Lanza E, Nielsen E, Galizzi A, Mazza G. Genetic and physiological studies on the site of action of distamycin A. Antimicrob Agents Chemother. 1975;8:370-6.
9. Schneider GP, Salcedo R, Dong HF, Kleinman HK, Oppenheim JJ, Howard ZOM. Suradista NSC 651016 inhibits the angiogenic activity of CXCL12-stromal cell-derived factor 1alpha. Clin Cancer Res. 2002;8:3955-60.
10. Groen HJ, de Vries EG, Wynendaele W, van der Graaf WT, Fokkema E, Lechuga MJ, et al. PNU-145156E, a novel angiogenesis inhibitor, in patients with solid tumors: a phase I and pharmacokinetic study. Clin Cancer Res. 2001;7:3928-33.
11. Clanton DJ, Buckheit Jr RW, Terpening SJ, Kiser R, Mongelli N, Lombardi Borgia A, et al. Novel sulfonated and phosphonated analogs of distamycin which inhibit the replication of HIV. Antiviral Res. 1995;27:335-54.
12. Howard ZOM, Oppenheim JJ, Hollingshead MG, Covey JM, Bigelow J, McCormack JJ, et al. Inhibition of in vitro and in vivo HIV replication by a distamycin analogue that interferes with chemokine receptor function: a candidate for chemotherapeutic and microbicidal application. J Med Chem. 1998;41:2184-93.
13. Moore JP, McKeating JA, Weiss RA, Sattentau QJ. Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science. 1990;250:1139-42.
14. Biswas P, Poli G, Kinter AL, Justement JS, Stanley SK, Maury WJ, et al. Interferon gamma induces the expression of human immunodeficiency virus in persistently infected promonocytic cells (U1) and redirects the production of virions to intracytoplasmic vacuoles in phorbol myristate acetate-differentiated U1 cells. J Exp Med. 1992;176:739-50.
15. Lusso P, Cocchi F, Balotta C, Markham PD, Louie A, Farci P, et al. Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1. J Virol. 1995;69:3712-20.
16. Smith SD, Shatsky M, Cohen PS, Warnke R, Link MP, Glader BE. Monoclonal antibody and enzymatic profiles of human malignant T-lymphoid cells and derived cell lines. Cancer Res. 1984;44:5657-60.
17. Dey B, Berger EA. Vaccinia-based reporter gene cell-fusion assays to quantitate functional interactions of HIV envelope glycoprotein with receptors. Curr Protoc Immunol. 2003;Chapter 12(Unit 12):10.
18. Platt EJ, Bilska M, Kozak SL, Kabat D, Montefiori DC. Evidence that ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1. J Virol. 2009;83:8289-92.
19. Burastero SE, Frigerio B, Lopalco L, Sironi F, Breda D, Longhi R, et al. Broad-spectrum inhibition of HIV-1 by a monoclonal antibody directed against a gp120-induced epitope of CD4. Plos One. 2011;6:e22081.
20. Tscherne DM, Manicassamy B, Garcia-Sastre A. An enzymatic virus-like particle assay for sensitive detection of virus entry. J Virol Methods. 2010;163:336-43.
21. Santoro F, Kennedy PE, Locatelli G, Malnati MS, Berger EA, Lusso P. CD46 is a cellular receptor for human herpesvirus 6. Cell. 1999;99:817-27.
22. Biswas P, Smith CA, Goletti D, Hardy EC, Jackson RW, Fauci AS. Cross-linking of CD30 induces HIV expression in chronically infected T cells. Immunity. 1995;2:587-96.
23. Cassol E, Alfano M, Biswas P, Poli G. Monocyte-derived macrophages and myeloid cell lines as targets of HIV-1 replication and persistence. J Leukoc Biol. 2006;80:1018-30.
24. De Clercq E. Suramin: a potent inhibitor of the reverse transcriptase of RNA tumor viruses. Cancer Lett. 1979;8:9-22.
25. Nussbaum O, Broder CC, Berger EA. Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating cell fusion-dependent reporter gene activation. J Virol. 1994;68:5411-22.
26. Burton DR, Ahmed R, Barouch DH, Butera ST, Crotty S, Godzik A, et al. A blueprint for HIV vaccine discovery. Cell Host Microbe. 2012;12:396-407.
27. Sanders RW, Venturi M, Schiffner L, Kalyanaraman R, Katinger H, Lloyd KO, et al. The mannose-dependent epitope for neutralizing antibody 2G12 on Human Immunodeficiency Virus type 1 glycoprotein gp120. J Virol. 2002;76:7293-305.
28. Hioe CE, Tuen M, Chien Jr PC, Jones G, Ratto-Kim S, Norris PJ, et al. Inhibition of human immunodeficiency virus type 1 gp120 presentation to CD4 T cells by antibodies specific for the CD4 binding domain of gp120. J Virol. 2001;75:10950-7.
29. Georgiev IS, Gordon Joyce M, Zhou T, Kwong PD. Elicitation of HIV-1-neutralizing antibodies against the CD4-binding site. Curr Opin HIV AIDS. 2013;8:382-92.
30. Huang CC, Venturi M, Majeed S, Moore MJ, Phogat S, Zhang M-Y, et al. Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. Proc Natl Acad Sci U S A. 2003;101:2706-11.
31. Yahi N, Sabatier J-M, Nickeln P, Mabrouk K, Gonzalez-Scaranol F, Fantini J. Suramin inhibits binding of the V3 region of HIV-1 envelope glycoprotein gp120 to galactosylceramide, the receptor for HIV-1 gp120 on human colon epithelial cells. J Biol Chem. 1994;269:24349-53.
32. Castagna A, Biswas P, Beretta A, Lazzarin A. The appealing story of HIV entry inhibitors: from discovery of biological mechanisms to drug development. Drugs. 2005;65:879-904.
33. Lusso P. HIV and the chemokine system: 10 years later. EMBO J. 2006;25:447-56.
34. Furci L, Tolazzi M, Sironi F, Vassena L, Lusso P. Inhibition of HIV-1 infection by human alpha-defensin-5, a natural antimicrobial peptide expressed in the genital and intestinal mucosae. PLoS One. 2012;7:e45208.
35. Lazzarin A, Clotet B, Cooper D, Reynes J, Arastéh K, Nelson M, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med. 2003;348:2186-95.
36. Fätkenheuer G, Pozniak AL, Johnson MA, Plettenberg A, Staszewski S, Hoepelman AI, et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med. 2005;11:1170-2.
37. Biswas P, Nozza S, Scarlatti G, Lazzarin A, Tambussi G. Oral CCR5 inhibitors: will they make it through? Expert Opin Invest Drugs. 2006;15:451-64.
38. Brumme ZL, Goodrich J, Mayer HB, Brumme CJ, Henrick BM, Wynhoven B, et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis. 2005;192:466-74.
39. Moyle GJ, Wildfire A, Mandalia S, Mayer H, Goodrich J, Whitcomb J, et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis. 2005;191:866-72.
40. Hunt PW, Harrigan PR, Huang W, Bates M, Williamson DW, McCune JM, et al. Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis. 2006;194:926-30.
41. Melby T, Despirito M, Demasi R, Heilek-Snyder G, Greenberg ML, Graham N. HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response. J Infect Dis. 2006;194:238-46.
42. Wilkin TJ, Su Z, Kuritzkes DR, Hughes M, Flexner C, Gross R, et al. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis. 2007;44:591-5.
43. Frange P, Galimand J, Goujard C, Deveau C, Ghosn J, Rouzioux C, et al. High frequency of X4/DM-tropic viruses in PBMC samples from patients with primary HIV-1 subtype-B infection in 1996-2007: the French ANRS CO06 PRIMO Cohort Study. J Antimicrob Chemother. 2009;64:135-41.
44. Goetz MB, Leduc R, Kostman JR, Labriola AM, Lie Y, Weidler J, et al. Relationship between HIV coreceptor tropism and disease progression in persons with untreated chronic HIV infection. J Acquir Immune Defic Syndr. 2009;50:259-66.
45. Nozza S, Canducci F, Galli L, Cozzi-Lepri A, Capobianchi MR, Ceresola ER, et al. Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1-infected naive patients with high CD4 counts. J Antimicrob Chemother. 2012;67:1224-7.
46. Saag M, Goodrich J, Fätkenheuer G, Clotet B, Clumeck N, Sullivan J, et al. A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. J Infect Dis. 2009;199:1638-47.
47. Liu T, Huang B, Zhan P, De Clercq E, Liu X. Discovery of small molecular inhibitors targeting HIV-1 gp120-CD4 interaction drived from BMS-378806. Eur J Med Chem. 2014;86:481-90.
48. Reddy MB, Morcos PN, Le Pogam S, Ou Y, Frank K, Lave T, et al. Pharmacokinetic/pharmacodynamic predictors of clinical potency for hepatitis C virus nonnucleoside polymerase and protease inhibitors. Antimicrob Agents Chemother. 2012;56:3144-56.
49. Spreen WR, Margolis DA, Pottage Jr GJ. Long-acting injectable antiretrovirals for HIV treatment and prevention. Curr Opin HIV AIDS. 2013;8:565-71.
50. Coutsoudis A, Kwaan L, Thomson M. Prevention of vertical transmission of HIV-1 in resource-limited settings. Expert Rev Anti Infect Ther. 2010;8:1163-75.
51. Fruehauf S. Current clinical indications for Plerixafor. Transfus Med Hemother. 2013;40:246-50.
52. Fätkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med. 2008;359:1442-55.
53. Madani N, Schön A, Princiotto AM, LaLonde JM, Courter JR, Takahiro Soeta T, et al. Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120. Cell Structure. 2008;16:1689-701.
54. Narumi T, Ochiai C, Yoshimura K, Harada S, Tanaka T, Nomura W, et al. CD4 mimics targeting the HIV entry mechanism and their hybrid molecules with a CXCR4 antagonist. Biorg Med Chem Lett. 2010;20:5853-8.